Recent quotes:

Health Benefits Shared by Psychedelics, Yoga, and Meditation -- Science of Us

Last year, Enzo Tagliazucchi, a postdoc at the Netherlands Institute for Neuroscience, co-led a brain-imaging study in Current Biology on LSD-induced ego dissolution, and found that the state was associated with increased connectivity between several brain areas. In explaining to me why that dissolution might be therapeutically helpful, he said that the entire psychedelic experience — even the challenging parts — has a way of “extracting the patient from his or her usual patterns of thought and contemplat[ing] upon them from a vantage point,” he explained over email. The dissolution itself seemed to play a direct role in the case of anxiety in terminal cancer patients, he added. It’s a catalyst for epiphany. “In a typical ego-dissolution experience, the user feels the boundaries between his or her body and the rest of the universe dissolve, and becomes ‘one’ with the surroundings,” he added. “This might lead to feelings of transcendence or permanence in the patients, making them realize that even after their death they will still be part of something ‘larger.’”

Single dose of hallucinogenic drug psilocybin relieves anxiety and depression in patients with advanced cancer | EurekAlert! Science News

Published in the Journal of Psychopharmacology online Dec.1, the study showed that one-time treatment with the hallucinogenic drug psilocybin -- whose use required federal waivers because it is a banned substance -- quickly brought relief from distress that then lasted for more than six months in 80 percent of the 29 study subjects monitored, based on clinical evaluation scores for anxiety and depression. The NYU Langone-led study was published side by side with a similar study from Johns Hopkins. Study results were also endorsed in 11 accompanying editorials from leading experts in psychiatry, addiction, and palliative care. "Our results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress," says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone. "If larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication -- dispensed under strict control -- to alleviate the distress that increases suicide rates among cancer patients," says Ross, also an associate professor of psychiatry at NYU School of Medicine. Study co-investigator Jeffrey Guss, MD, a clinical assistant professor of psychiatry at NYU Langone, notes that psilocybin has been studied for decades and has an established safety profile. Study participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions. Although the neurological benefits of psilocybin are not completely understood, it has been proven to activate parts of the brain also impacted by the signaling chemical serotonin, which is known to control mood and anxiety. Serotonin imbalances have also been linked to depression. For the study, half of the participants were randomly assigned to receive a 0.3 milligrams per kilogram dose of psilocybin while the rest received a vitamin placebo (250 milligrams of niacin) known to produce a "rush" that mimics a hallucinogenic drug experience. Approximately half way through the study's monitoring period (after seven weeks), all participants switched treatments. Those who initially received psilocybin took a single dose of placebo, and those who first took niacin, then received psilocybin. Neither patients nor researchers knew who had first received psilocybin or placebo. Guss says, "The randomization, placebo control, and double-blind procedures maximized the validity of the study results." One of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study's extended monitoring period -- specifically, eight months for those who took psilocybin first.